Abstract library

385 results for "men1 syndrome".
#1093 38 Years of Experience in a Single Centre on Neuroendocrine Pancreatico-Duodenal Tumors in Multiple Endocrine Neoplasia Type 1 Syndrome
Introduction: Multiple Endocrine Neoplasia type 1 (MEN1) syndrome has an autosomal dominant transmission. Combination of tumors: parathyroid, pituitary and pancreatico-duodenal (PD) NETs. PD NETs in MEN1 syndrome show propensity for malignant degeneration.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Doctor Valbona Lico
#1722 New MEN-1 Gene Mutation Implicated in Familiar MEN-1 Syndrome Onset
Introduction: Multiple endocrine neoplasia type 1 (MEN1) is a rare genetic syndrome associated with an increased risk of developing parathyroid, pituitary and pancreatic neuroendocrine tumors. MEN1 has an autosomal dominant pattern of hereditability and it is usually related to mutations in menin coding gene
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: MD Elisabetta Grego
#2132 Survival and Prognosis in Patients with Duodeno-Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1 Syndrome
Introduction: Multiple endocrine neoplasia type 1 (MEN1) is an inherited syndrome, affecting multiple endocrine glands. Duodeno-pancreatic neuroendocrine tumors (DP-NET) represent the most frequent type of NET in MEN1. Their prognosis and treatment strategy is debated.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: MD Roberta Modica
#1756 Somatostatin Analogs in Patients with Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndrome: Efficacy and Safety
Introduction: Zollinger-Ellison syndrome (ZES) can cause severe complications. In multiple endocrine neoplasia type 1 (MEN1) related ZES, surgery has a controversial role and proton pump inhibitors (PPI) are usually first-line therapy, although some concerns regarding long-term use. Somatostatin analogs (SSA) both reduce hypergastrinemia and have an antiproliferative role.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Roberta Modica
#1509 MEN1 Syndrome with Pancreatic Involvement and Synchronous Lung Adenocarcinoma: A Case Report
Introduction: Lung lesions in MEN1 patients makes us consider firstly a neuroendocrine tumor (NET) as carcinoids are part of MEN1 syndrome.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Doctor Valbona Liço
Keywords: men1
#1236 Management and Clinical Outcome of Patients with MEN 1 Disease Presenting Non Functioning Pancreatic Neuroendocrine Neoplasms (NF-pNEN) ≤ 2 cm
Introduction: The role of surgery for NF-pNEN ≤ 2 cm in MEN1 patients is still controversial.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Domenico Tamburrino
#1438 An Unusual Phenotype of Multiple Endocrine Neoplasia Type 1 with a Small Intestine Neuroendocrine Tumor Associated with Large Deletion of the MEN1 Gene
Introduction: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant inherited tumor syndrome that is caused by germline mutations in the Menin suppressor gene on chromosome 11q13. Small intestine neuroendocrine neoplasias (SI-NEN) are currently not considered to be part of the phenotype of the MEN1-syndrome.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: MD Jerena Manoharan
#1858 Quality of Life in Patients with Multiple Endocrine Neoplasia Type I (MEN1): Results from the Dutch MEN1 Study Group
Introduction: Multiple Endocrine neoplasia type 1 (MEN1) is a hereditary tumor syndrome, characterized by an increased lifetime risk of benign and malignant endocrine tumors in various organs. Data on quality of life (QoL) in patients with MEN1 are scarce, whereas QoL is considered an important treatment outcome.
Conference: 14th Annual ENETS conference (2017)
Category: ...none of the above
Presenting Author: MD Rachel van Leeuwaarde
Keywords: MEN1, QoL
#2176 New MENIN Mutation Associated with Familial Isolated Hyperparathyroidism. Clinical Case of Three Young Sisters.
Introduction: The primary hyperparathyroidism (PHPT) is a sporadic disorder in the majority of cases, and only 5-10% of cases are associated with familial syndromes. The following familial syndromes associated with PHPT are known to date: multiple endocrine neoplasia type 1 (MEN1), type 2A (MEN2A), type 4 (MEN4), hyperparathyroidism-jaw tumor syndrome (HPT-JT), familial hypocalciuric hypercalcemia (FHH), neonatal severe hyperparathyroidism (NSHPT) and familial isolated hyperparathyroidism (FIHP). FIHP is defined as hereditary PHPT without the association with other diseases or tumors and may be caused by mutations in MEN1, HRPT2, or CASR genes.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Julia Krupinova
#40 Clinical and prognostic implications of the genetic diagnosis of hereditary NET syndromes in asymptomatic patients
Introduction: Neuroendocrine tumors (NETs) are rare neoplasms, heterogeneous, and with variable biological behavior. NETs can be sporadic or they can arise in complex endocrine hereditary syndromes such as Multiple Endocrine Neoplasias (MEN), Familial Paragangliomatosis (FPGL), Neurofibromatosis type 1 (NF1), von Hippel-Lindau Disease (VHL), Tuberous Sclerosis (TSC) and Carney Complex (CC). By performing genetic screening, patients with hereditary NETs can be identified before the development of tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Antongiulio Faggiano